Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
View Top Employees from Castle Biosciences, Inc.Website | http://www.castlebiosciences.com |
Ticker | CSTL |
Revenue | $51 million |
Funding | $412.5 million |
Employees | 492 (476 on RocketReach) |
Founded | 2008 |
Address | 505 S Friendswood Dr Suite 401, Friendswood, Texas 77546, US |
Phone | (866) 788-9007 |
Fax | (866) 431-2924 |
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Diagnostic Cancer Testing, Healthcare, Science and Engineering, Uveal Melanoma, Health Care, Cutaneous Melanoma, Health Diagnostics, Mesothelioma, Melanoma |
Web Rank | 7 Million |
Keywords | Cancer Diagnosis |
Competitors | 3D Signatures Inc, Agendia, Cernostics, Chronix Biomedical, Inc., DermTech |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 62 Companies, NAICS Code 62151 Companies, NAICS Code 6215 Companies, NAICS Code 621 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Castle Biosciences, Inc. employee's phone or email?
The Castle Biosciences, Inc. annual revenue was $51 million in 2024.
Bob Cook is the Senior Vice President, R and D of Castle Biosciences, Inc..
476 people are employed at Castle Biosciences, Inc..
Castle Biosciences, Inc. is based in Friendswood, Texas.
The NAICS codes for Castle Biosciences, Inc. are [62, 62151, 6215, 621, 3254, 32, 325, 32541].
The SIC codes for Castle Biosciences, Inc. are [28, 283].